The WoVen Podcast
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2022 Canaan |
Latest for Day One Biopharmaceuticals
Endpoints News: With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round
Nine months after emerging from stealth, Day One Biopharmaceuticals announces a $130M Series B raise.
FierceBiotech: A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug
Day One Biopharmaceuticals has reported promising interim data from a pivotal trial of tovorafenib in relapsed pediatric low-grade glioma, marking...
Endpoints News: It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer
Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain...
A milestone in targeted oncology and looking ahead
In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
Fierce Biotech: Childhood cancer-focused Day One snags Gilead alum Bender for CEO
Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is...
The Long Run Podcast: Julie Grant and Sam Blackman on cancer drugs for kids
Fierce Biotech: Childhood cancer-focused Day One banks $130M for pan-RAF inhibitor
SF Business Times: Targeting more childhood cancers, Day One raises $130M
Julie Grant: Cancer drug development comes of age - The inspiration behind Day One Biopharmaceuticals
The inspiration for Day One Biopharmaceuticals emerged from an inequity in patient care highlighted by leaders in the pediatric oncology community.
STAT News: Startup Spotlight - Aiming to speed precision cancer therapies to children
Day One — named for the conversations clinicians have with parents when they first tell them their child has cancer and how they hope to treat it —...
FierceBiotech: Day One debuts with $60M to change cancer care—starting with children
Day One is launching to develop new cancer treatments for children, but that could be used in adult patients, too.
WSJ Pro VC: Cancer drugmaker Day One Biopharmaceuticals launches with $60 million
The startup aims to develop cancer treatments for children and adults.
Timmerman Report: No longer an afterthought -- Day One raises $130M for childhood cancer therapies
BioCentury: Gilead BD head Bender takes top job at pediatric cancer start-up Day One